University of Cincinnati
02/05/2026 | Press release | Distributed by Public on 02/05/2026 19:36
'Time is brain' again, now for control of intracerebral hemorrhage
'Time is brain' again, now for control of intracerebral hemorrhage
MedPage Today highlights UC-led research
2 minute read February 5, 2026 Share on facebook Share on Twitter Share on LinkedIn Share on Reddit Print StoryLike
MedPage Today highlighted research led by the University of Cincinnati's Joseph Broderick that found administering a synthetic protein can reduce bleeding and improve outcomes for certain patients at the highest risk of continued bleeding following a type of stroke called an intracerebral hemorrhage (ICH).
Broderick, MD, presented results of the FASTEST trial at the International Stroke Conference, with results also published in The Lancet. The trial tested a drug called recombinant factor VIIa (rFVIIa), a synthetic version of a protein the body naturally produces to help stop bleeding.
Overall findings of the trial were neutral, and the trial was ended early for futility. While the drug did slow bleeding overall, there was a lack of evidence of benefit for clinical outcomes in the overall study population.
However, researchers found the drug was most effective in people who have what is called a "spot sign" on computed tomography (CT) brain imaging and for patients treated within 90 minutes of stroke onset.
"We think we now have a very clear roadmap for the first hemostatic therapy for intracerebral hemorrhage," said Broderick, professor in UC's College of Medicine, senior adviser at the UC Gardner Neuroscience Institute and director of the NIH StrokeNet National Coordinating Center. "The closer to time zero you can treat, the less bleeding you are likely to have with rFVIIa treatment."
Read the MedPage Today article.
Read more about the trial results.
Featured photo at top of Dr. Broderick. Photo/Joseph Fuqua II/University of Cincinnati.
Tags
Related Stories
1
Trial finds new drug safe, effective to treat deadliest form of epilepsy
October 23, 2024
MSN highlighted research presented by the University of Cincinnati's Brandon Foreman that found ganaxolone is a safe and effective treatment for refractory status epilepticus.
2
UC marks 4 years saving lives with mobile stroke unit
August 15, 2024
The University of Cincinnati's Christopher Richards spoke with Local 12 about the four-year anniversary of the mobile stroke unit that can bring the emergency department directly to patients.
3
Jacksonville media: New stroke research aims to help predict recovery
April 18, 2023
Jacksonville, Florida television news station WJXT highlighted the VERIFY study being led by University of Cincinnati researchers that will examine if certain biomarkers can predict the likelihood that a patient will recover motor functions following a stroke.
University of Cincinnati published this content on February 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on February 06, 2026 at 01:36 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]